CN1102985A - Nearsight prevention eye drop solution - Google Patents

Nearsight prevention eye drop solution Download PDF

Info

Publication number
CN1102985A
CN1102985A CN93115035A CN93115035A CN1102985A CN 1102985 A CN1102985 A CN 1102985A CN 93115035 A CN93115035 A CN 93115035A CN 93115035 A CN93115035 A CN 93115035A CN 1102985 A CN1102985 A CN 1102985A
Authority
CN
China
Prior art keywords
eye drop
effect
myopia
eyeball
layer powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN93115035A
Other languages
Chinese (zh)
Other versions
CN1047523C (en
Inventor
张甘霖
徐辉碧
张海
刘琼
黄开勋
杨继林
高秋华
范华汉
杨祥良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan Tiantian Pharmaceutical Co ltd
Huazhong University of Science and Technology
Original Assignee
Huazhong University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huazhong University of Science and Technology filed Critical Huazhong University of Science and Technology
Priority to CN93115035A priority Critical patent/CN1047523C/en
Publication of CN1102985A publication Critical patent/CN1102985A/en
Application granted granted Critical
Publication of CN1047523C publication Critical patent/CN1047523C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invented eyedrops has strong antispasm action to the ciliary muscle, can both cure galse myopia and improve the eyeball nourishment and metabolism to make the eyeball be well developed, thus taking the effect for treating myopia by looking into both its root cause and symptoms, in addition it is convenient for application and there is no any harmful sede effect. Said invention uses the hydrolytic liquid of nacreous layer powder as base component and is preparted up by adding trace elements Zn, Cu, Se, Cd and Ca which are closely related to eye sight and proper amount vitamins.

Description

Nearsight prevention eye drop solution
The present invention is a kind of eye drop of preventing and treating adolescent myopia.This eye drop can prevent, treat pseudomyopia, can prevent and treat true myopia on certain program again.
Relevant bathomorphic Therapeutic Method is a lot.True myopia and degenerative myopia are adopted operative therapy both at home and abroad more at present, pseudomyopia is adopted physiotherapy and pharmacotherapy more.In the existing medicine, a class is regulated anxiety for removing eyes, thus the medicine that pseudomyopia is disappeared, as atropic category, epinephrine etc.Such medicine has very strong releasing ciliary spasm effect, but only can treat pseudomyopia.Though recent instant effect, curative effect is short, cures the symptoms, not the disease.Another kind ofly be nutrition and metabolism situation of improving each tissue of ophthalmic, the medicine that strengthens ocular tissue's function, as vitamins, minerals, protein-based, heparin etc.Though such medicine can effect a permanent cure, short-term effect is not remarkable.The present invention is on the said medicine basis, utilizes Margarita layer powder and trace element to develop.This eye drop can be removed ciliary spasm, and the treatment pseudomyopia can be improved eyeball nutrition, metabolism status again, makes eyeball development normal, plays the effect to near-sighted treating both the principal and secondary aspects of a disease.
Purpose of the present invention is intended to remove ciliary spasm, prevents that eyeball is out of shape, shortens the axial length of near-sighted eyeball, to reach prevention and treatment teenage pseudomyopia, the purpose of mixed myopia and low true myopia.Thereby improved and had the situation that similar eye drop can only be treated pseudomyopia both at home and abroad now.
The present invention is basic components with the Margarita layer powder hydrolysate, and is formulated with the closely-related trace element zinc of vision, copper, selenium, chromium, calcium and other active component in addition.The main effect of each composition is as follows:
Contain protein, polypeptide and a large amount of aminoacid and various trace elements in the Margarita layer powder hydrolysate.Its chemical constituent is almost similar to Margarita hydrolyzed solution.Think on the traditional Chinese medical science have " detoxifcation makes eye bright ", " controlling the order skin ", " controlling cataracta tunica albuginea in the eye " effect.Modern medicine thinks that aminoacids complex can participate in ocular tissue's metabolism directly, collagen decomposition enzyme and the mucopolysaccharide body catabolic enzyme that causes the crystal muddiness played inhibitory action, enzyme series to contained sulfydryl in the crystal has the effect of living of composing, suppress of the transformation of transparent soluble protein, help crystal to strengthen transparency to opaque insoluble protein.
Zinc has specific function keeping visual aspects, up to 4%, it participates in the metabolism and the conveying of the synthetic and vitamin A of nucleic acid protein at the vision position of normal eye zinc content, keeps the normal structure state of retinal pigment epithelium, keep normal visual function, improve the vision at dusk.
Copper content in the human eye corpus ciliare choroideae is higher.It participates in the formation of pigment, is the active ingredient of more than 30 kind of metalloenzyme such as cytochrome C oxidase, ceruloplasmin.Copper contains quantity not sufficient, will cause the pigment dyssynthesis, cause primary pigmentary degeneration of the retina; Also influence tissues such as eye muscle and crystalline lens simultaneously.
Selenium is relevant with visual acuity, and its content in the human eye retina is about 7 μ g.Selenium deficiency or deficiency will cause diseases such as senile cataract and liability myopia.
Chromium takes place relevant with myopia.When human body chromium content descended, the effect of insulin obviously reduced, and caused the utilization generation obstacle of sugar, and plasma osmotic pressure rises, and causes the change of aqueous humor osmotic pressure, impelled crystal to become protruding, and diopter increases, and causes myopia.
Calcium is also relevant with myopia.The reduction of free calcium in the blood can make the neuromuscular excitement increase, and causes muscle spasm.Ciliary spasm is promptly relevant with calcium deficiency, and it is one of reason that causes teenage pseudomyopia.
The present invention mainly acts on according to above-mentioned each composition, and it is as follows to fill a prescription: Margarita layer powder hydrolysate, wherein contain a large amount of aminoacid and various trace elements.Its content is:: aspartic acid: 5~10 μ g/ml, serine: 5~10 μ g/ml, glutamic acid: 1~5 μ g/ml, glycine: 10~15 μ g/ml, alanine: 5~10 μ g/ml, cysteine: 1~5 μ g/ml, valine: 1~5 μ g/ml, methionine: 5~10 μ g/ml, leucine: 0.5~1 μ g/ml, phenylalanine: 5~10 μ g/ml, lysine: 0.5~1 μ g/ml, trace copper: 0.001~0.1 μ g/ml, trace elements iron: 0.001~0.1 μ g/ml.On this basis, add zinc gluconate 0.01~5mg/ml, sodium selenite 0.002~0.10mg/ml, chromium trichloride 0.0001~0.01mg/ml, and vitamin: 0.01~5mg/ml.
The present invention uses through the adolescent myopia patient, vision all is significantly improved as a result, the former vision that has is 0.2, with this eye drop eye drip one month, and vision restoration to 1.0 twenty-twenty vision scope, and drug withdrawal vision stability, demonstrate tool long-term efficacy just, do not have any harmful side effect again, and easy to use, drip every day three times, each 1~2 gets final product.
The present invention not only drug effect is better than existing medicine both at home and abroad, and does not have expensive especially composition, and anticipated price can be vast ruck and accepts, and easy to use.Therefore, behind the launch products, bring the hope of healing will for vast adolescent myopia patient, produce very big social benefit and economic benefit.

Claims (2)

1, the bathomorphic eye drop of a kind of control, it is characterized in that: the composition of eye drop is: be basic components with the Margarita layer powder hydrolysate, add zinc gluconate 0.01~5mg/ml, sodium selenite 0.002~0.10mg/ml, chromium trichloride 0.0001~0.01mg/ml, and vitamin: 0.01~5mg/ml.
2, according to the described eye drop of claim 1, the composition that it is characterized in that Margarita layer powder hydrolysate is: aspartic acid: 5~10 μ g/ml, serine: 5~10 μ g/ml, glutamic acid: 1~5 μ g/ml, glycine: 10~15 μ g/ml, alanine: 5~10 μ g/ml, cysteine: 1~5 μ g/ml, valine: 1~5 μ g/ml, methionine: 5~10 μ g/ml, leucine: 0.5~1 μ g/ml, phenylalanine: 5~10 μ g/ml, lysine: 0.5~1 μ g/ml and trace copper: 0.001~0.1 μ g/ml, trace elements iron: 0.001~0.1 μ g/ml.
CN93115035A 1993-11-23 1993-11-23 Nearsight prevention eye drop solution Expired - Lifetime CN1047523C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN93115035A CN1047523C (en) 1993-11-23 1993-11-23 Nearsight prevention eye drop solution

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN93115035A CN1047523C (en) 1993-11-23 1993-11-23 Nearsight prevention eye drop solution

Publications (2)

Publication Number Publication Date
CN1102985A true CN1102985A (en) 1995-05-31
CN1047523C CN1047523C (en) 1999-12-22

Family

ID=4990751

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93115035A Expired - Lifetime CN1047523C (en) 1993-11-23 1993-11-23 Nearsight prevention eye drop solution

Country Status (1)

Country Link
CN (1) CN1047523C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105663160A (en) * 2016-04-14 2016-06-15 齐齐哈尔市前进医药有限责任公司 Eye element eye drops and preparation method thereof
JP2021509902A (en) * 2018-01-05 2021-04-08 ユニバーシティー オブ ユタ リサーチ ファウンデーションUniversity of Utah Research Foundation Treatment of myopia progression

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105663160A (en) * 2016-04-14 2016-06-15 齐齐哈尔市前进医药有限责任公司 Eye element eye drops and preparation method thereof
JP2021509902A (en) * 2018-01-05 2021-04-08 ユニバーシティー オブ ユタ リサーチ ファウンデーションUniversity of Utah Research Foundation Treatment of myopia progression
JP7324208B2 (en) 2018-01-05 2023-08-09 ユニバーシティー オブ ユタ リサーチ ファウンデーション Treatment of myopia progression

Also Published As

Publication number Publication date
CN1047523C (en) 1999-12-22

Similar Documents

Publication Publication Date Title
CN110496215A (en) A kind of aqueous ophthalmic solution and preparation method thereof for treating presbyopia
CN102178925A (en) Novel eyesight protective agent lutein ophthalmic preparation
CN100453086C (en) Gel for removing ocular by ice pearl and its preparation
CN1824056B (en) Applicaiton of a Chinese-western medicine combined composition for preparing medicine and food dual purpose nutritive product for preventing and treating cataract
CN1824042B (en) Applicaiton of a composition for preparing medicine and food dual purpose nutritive product for preventing and treating computer vision syndrome
CN100384452C (en) Medicine and food dual purpose nutritive product for preventing and treating computer vision syndrome and its manufacturing method
CN1824050B (en) Applicaiton of a composition for preparing medicine and food dual purpose nutritive product for preventing and treating xeroma
CN1047523C (en) Nearsight prevention eye drop solution
EP0048473A1 (en) A novel pharmaceutical composition containing zinc salts
CN100376234C (en) medicine and food dual purpose vitamin microelement nutritive product for preventing and treating synchysis and its manufacturing method
CN100376235C (en) Medicine and food dual purpose nutritive product for preventing and treating synchysis and its manufacturing method
CN1823821A (en) Vitamin and microelements nutritive product for preventing and treating vision syndrome due to computer and its manufacturing method
CN103417525B (en) Application of zinc gluconate tablets and six vitamin pills in treating ametropic eyes
CN1259081C (en) Oral liquid for treating ophthalmic diseases
CN101129698B (en) Eye drops containing turmeric extractive and preparation method thereof
CN104474509A (en) Medicine patch for conditioning eye refraction and preparation method of medicine patch
CN110559314A (en) Composition for protecting eyesight
CN2890976Y (en) Cornea forming contact lens
CN1127960C (en) Eyesight improving medicine liquid
CN104436156A (en) Eyesight protective agent xanthophyll eye preparation and preparation process thereof
CN1106669A (en) Eye drops for prevention and cure of cataract
CN108936689A (en) Adjust the oral solution and preparation method thereof of immunity
CN106074626A (en) A kind of alleviate dry and astringent antibacterial liquid of eye and preparation method thereof
CN102106796A (en) Nutritional health-care product for adjusting visual performance
CN101804057A (en) Chuagxiongzine ophthalmic preparation

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: HUAZHONG SCIENCE & TECH. UNIV.

Free format text: FORMER NAME OR ADDRESS: HUAZHONG SCIENCE AND ENGINEERING UNIVERSITY

CP03 Change of name, title or address

Address after: 430074 Hubei city of Wuhan province Wuchang Luo Yu Road, No. 151

Patentee after: Huazhong University of Science and Technology

Address before: 430074 Hubei city of Wuhan province Wuchang Luo Yu Road, No. 151

Patentee before: Huazhong University of Science and Technology

ASS Succession or assignment of patent right

Owner name: WUHAN TIANTIANMING PRESCRIBED MEDICINE CO., LTD.

Free format text: FORMER OWNER: HUAZHONG SCIENCE + TECH. UNIV.

Effective date: 20060623

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: HUAZHONG SCIENCE & TECH. UNIV.

Free format text: FORMER NAME OR ADDRESS: HUAZHONG SCIENCE AND ENGINEERING UNIVERSITY

CP03 Change of name, title or address

Address after: 430074 Hubei city of Wuhan province Wuchang Luo Yu Road, No. 1037

Patentee after: Huazhong University of Science and Technology

Address before: 430074 Hubei city of Wuhan province Wuchang Luo Yu Road, No. 151

Patentee before: Huazhong University of Science and Technology

TR01 Transfer of patent right

Effective date of registration: 20060623

Address after: 430035 Hubei Wuhan East and West Lake Wu Wu garden Eastern District

Patentee after: Wuhan Tiantian Pharmaceutical Co.,Ltd.

Address before: 430074 Hubei city of Wuhan province Wuchang Luo Yu Road, No. 1037

Patentee before: Huazhong University of Science and Technology

CI01 Publication of corrected invention patent application

Correction item: Patentee

Correct: Wuhan Tiantianming Pharmaceutical Industry Co., Ltd.

False: Wuhan Tiantian Pharmaceutical Co., Ltd.

Number: 31

Page: 1033

Volume: 22

ERR Gazette correction

Free format text: CORRECT: PATENTEE; FROM: WUHAN TIANTIANMING PRESCRIBED MEDICINE CO., LTD. TO: WUHAN TIANTIANMING PHARMACEUTICAL CO., LTD.

C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Chen Bin

Document name: Notice of conformity

Addressee: Chen Bin

Document name: Notification of Termination of Patent Right

C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Chen Bin

Document name: Notice of conformity

C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Chen Bin

Document name: Special business review memo

C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20131123

Granted publication date: 19991222